Zobrazeno 1 - 10 of 225 pro vyhledávání: '"Joaquín Borrás"'
1
Akademický článek
Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care
Autor: Isabel Castrejón, Laura Cano, María José Cuadrado, Joaquín Borrás, Maria Galindo, Tarek C. Salman-Monte, Carlos Amorós, Carmen San Román, Isabel Cabezas, Marta Comellas, Alejandro Muñoz
Publikováno v: BMC Rheumatology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Background Systemic lupus erythematosus (SLE) may result in great impact on patients’ quality of life, social relationships, and work productivity. The use of patient-reported outcome measures (PROMs) in routine care could help capture dis
Externí odkaz: https://doaj.org/article/05afc6b8f51d4f3281e6c4bfc717d363
Zobrazit plný text záznamu
3
Akademický článek
Cost-effectiveness analysis of ferric carboxymaltose iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
Autor: Federico Argüelles-Arias, Fernando Bermejo, Joaquín Borrás-Blasco, Eugeni Domènech, Beatriz Sicilia, José M. Huguet, Antonio Ramirez de Arellano, William J. Valentine, Barnaby Hunt
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron f
Externí odkaz: https://doaj.org/article/9dc02893f99d4ed581fece6ca07a0b62
Zobrazit plný text záznamu
4
Akademický článek
Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Autor: Xavier Cortes, Joaquín Borrás-Blasco, Jose Ramón Molés, Maia Boscá, Ernesto Cortés
Publikováno v: PLoS ONE, Vol 10, Iss 5, p e0128156 (2015)
To obtain preliminary safety and efficacy data on intravenous (IV) administration of infliximab (IFX) and ferric carboxymaltose (FCM) to inflammatory bowel disease (IBD) patients in a single treatment session.A two-phase non-interventional, observati
Externí odkaz: https://doaj.org/article/3f84611731ad452ea88aa9543228301d
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Persistence, Clinical and Economic Impact of Infliximab CT-P13 in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Naïve and Switched Patients: After 5 Years of Follow-Up
Autor: Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Dolores Rosique-Robles, Elvira Casterá
Publikováno v: Journal of Pharmacy and Nutrition Sciences. 12:74-79
Objective: Study the economic impact and persistence of Inflectra® in rheumatoid arthritis (RA), psoriatic arthropathy (PSA), psoriasis, ankylosing spondylitis (AS) naïve, and Remicade® switched patients. Methods: Retrospective observational cohor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5334a552771332758045b82ad0d13e93
https://doi.org/10.29169/1927-5951.2022.12.06
Zobrazit plný text záznamu
8
Humanization Guide of the Spanish Society of Hospital Pharmacy for patients with inflammatory immune-mediated diseases
Autor: Ana María, Álvarez-Díaz, Gabriel, Mercadal-Orfila, Esther, Ramírez-Herráiz, Joaquín, Borrás-Blasco
Publikováno v: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(6)
This study reports on the results of a project conducted by the Spanish Society of Hospital Pharmacy with patients with immune-mediated inflammatory diseases, with the following objectives: to understand the experience of patients living with these d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7441feef61e75ff37b0802f4b6c23d34
https://pubmed.ncbi.nlm.nih.gov/36520573
Zobrazit plný text záznamu
9
Evaluation of persistence, retention 'rate' and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis
Autor: Alejandro, Valcuende-Rosique, Joaquín, Borrás-Blasco, Sandra, Martínez-Badal, Xavier, Cortes, Celia, Aparicio-Rubio, Elvira, Casterá-Melchor
Publikováno v: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(5)
To compare the persistence, retention rate and prescription pattern of original infliximab and infliximab CT-P13 in biologic- naïve patients with ulcerative colitis.This was an ambispective study of biologic-naive patients with ulcerative colitis wh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e0b0c73bad0a1db69f8ae2383f15bfd3
https://pubmed.ncbi.nlm.nih.gov/36183230
Zobrazit plný text záznamu
10
Successful use of golimumab in a patient with ulcerative colitis refractory to infliximab and adalimumab
Autor: Joaquín Borrás-Blasco, Xavier Cortes, Jose Ramón Molés, Laura Flor, Beatriz Antequera, Elvira Casterá, Sergio Fernandez-Martinez
Publikováno v: Int. Journal of Clinical Pharmacology and Therapeutics. 59:257-260
OBJECTIVE To report a case of successful use of golimumab (GLB) in a patient with ulcerative colitis (UC) refractory to infliximab (IFX) and adalimumab (ADA). CASE SUMMARY A 60-year-old man was diagnosed with left UC and was given azathioprine 2.5 mg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11915edcc4130f3d23e0fe300a09bb79
https://doi.org/10.5414/cp202621
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje